Zambon Presents Results from the Two Phase 3 PROMIS Studies of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis at World Bronchiectasis Conference 2023

Data show inhalation via the I-neb Adaptive Aerosol Delivery System of colistimethate sodium (CMS) results in reduction of pulmonary exacerbations in...

Related Keywords

Milan ,Lombardia ,Italy ,New Zealand ,Israel ,Brazil ,Australia ,Belgium ,Netherlands ,China ,Switzerland ,United Kingdom ,Greece ,New York ,United States ,Portugal ,Argentina ,Germany ,Spain ,Boston ,Massachusetts ,Vicenza ,Veneto ,Canada ,Poland ,France ,America ,Italian ,Charles Haworth ,Prnewswire Zambon ,Ilaria Villa ,Lindsay Rocco ,James Chalmers ,Paola Castellani ,Development Program ,Elixir Health Public Relations ,Professor Of Respiratory Research ,University Of Dundee ,I Neb Adaptive Aerosol Delivery System ,Fast Track ,World Bronchiectasis Conference ,Registry Updates ,Colistimethate Sodium Delivered Via ,Respiratory Questionnaire ,Infectious Disease Product ,Respiratory Physician ,Cambridge Centre ,Lung Infection ,Royal Papworth Hospital ,Professor James Chalmers ,Respiratory Research ,Adaptive Aerosol Delivery System ,Life Questionnaire Bronchiectasis ,Adaptive Aerosol Delivery ,Zambon Spa ,Breath Therapeutics ,United States Media Contact ,Zambons Pa ,